Skip to main content

Table 1 Patient characteristics with and without metabolic syndrome

From: Association of HIV-infection, antiretroviral treatment and metabolic syndrome with large artery stiffness: a cross-sectional study

 

No Metabolic Syndrome

Metabolic Syndrome

(N = 113)

(N = 38)

Variable

Controls (n = 39)

HIV-1 untreated (n = 32)

HIV-1 cART (n = 42)

Controls (n = 10)

HIV-1 untreated (n = 16)

HIV-1 cART (n = 12)

Age, year

45 ± 3

44 ± 6

46 ± 5

45 ± 4

47 ± 5

47 ± 4

Men, %

69

28

29

50

13

25

Body mass, kg

67.8 ± 11.8

64.7 ± 9.7

58.5 ± 11.5a

81.1 ± 10.6c

71.2 ± 12.7c

75.0 ± 15.6c

BMI, kg/m2

24.8 ± 4.2

24.3 ± 3.9

22.5 ± 4.1a

30.4 ± 4.6c

26.7 ± 3.2c

28.9 ± 4.1c

Body fat, %

32 ± 9

35 ± 7

33 ± 8

38 ± 5c

40 ± 4c

40 ± 4c

Waist circumference, cm

85 ± 10

81 ± 7

81 ± 11

95 ± 8c

92 ± 9c

98 ± 6c

Systolic BP, mmHg

124 ± 12

126 ± 9

120 ± 11

135 ± 7c

135 ± 13c

131 ± 18c

Diastolic BP, mmHg

74 ± 7

76 ± 5

74 ± 8

79 ± 3c

79 ± 6

79 ± 6c

LDL-cholesterol, mmol/l

2.9 ± 0.9

2.5 ± 0.8

2.7 ± 1.0

3.1 ± 0.7

2.8 ± 1.1

3.2 ± 0.9

HDL-cholesterol, mmol/l

1.2 ± 0.4

1.1 ± 0.5

1.4 ± 0.6b

1.0 ± 0.6

0.8 ± 0.3

1.1 ± 0.3

Triglycerides, mmol/l

1.1 ± 0.7

1.0 ± 0.4

1.4 ± 1.1

2.3 ± 1.5c

1.3 ± 0.6

2.0 ± 1.2

Glucose, mmol/l

4.7 ± 0.6

4.5 ± 0.7

4.8 ± 0.6

5.0 ± 0.7

4.8 ± 0.9

4.7 ± 0.7

CD4 at enrollment, cells/μL

665 ± 142

289 ± 46b

666 ± 120

302 ± 41b

CD4 (most recent), cells/μL

493 ± 250d

494 ± 229d

430 ± 255d

480 ± 189d

Months of HIV-1 infection, median

21.5

29.3b

20.6

39.8b

Months cART, median

24.0

30.9

  1. Values are means ± SD unless otherwise noted. BMI body mass index, BP blood pressure, LDL low-density lipoprotein, HDL high-density lipoprotein, cART combined antiretroviral therapy, aP < 0.05 vs. within-group controls, bP < 0.05 vs. within-group HIV-1 untreated patients, cP < 0.05 vs. corresponding group without metabolic syndrome, d P < 0.01 vs. within-group CD4 at enrollment